Owlet secures approval for infant health monitoring tech in India

US-based Owlet, Inc., the pioneer of smart infant monitoring, has announced that the Central Drugs Standard Control Organization (CDSCO) approved Dream Sock^® for distribution.

This marks a significant milestone for the company as it now prepares to launch its integrated monitoring devices, including Dream Sock^®, Dream Sight^™, and Dream Duo^™, across India in early 2026.

With approval from the CDSCO, India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, Owlet becomes one of the few infant health technology companies to meet the region’s stringent medical device requirements, further validating its commitment to clinical rigor and innovation. As smartphone penetration exceeds 80% in urban centers, India’s connected-home environment provides a strong foundation for the adoption of Owlet’s technology.

Owlet’s technology supports India’s broader healthcare priorities of improving infant health outcomes and empowering parents with early detection tools. The company’s suite of award-winning products, expected to be available in India in early 2026 includes:

• Dream Sock, a wearable smart baby monitor that is designed for healthy infants between 0-18 months or 2.5-13.6 kg, tracks key vitals in real-time, such as oxygen level and pulse rate, along with sleep trends, providing clinically validated insights.
• Dream Sight, Owlet’s latest intelligent audio and video camera, which offers secure, high-definition monitoring for around-the-clock visibility while detecting motion, sound, and crying.
• Dream Duo, the ultimate all-in-one monitoring system, combines Dream Sock and Dream Sight for real-time vital alerts and a complete view of Baby’s wellness and sleep.
• Dream App, a simple, convenient App where families can view live health readings in real-time. Both the Dream App and the included Base Station provide notifications if measurements fall outside preset ranges.